These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28735051)

  • 1. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
    Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
    Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
    Jones RN; Flamm RK; Castanheira M; Sader HS; Smart JI; Mendes RE
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):184-187. PubMed ID: 28377166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
    J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Smart JI; Mendes RE
    Microb Drug Resist; 2017 Sep; 23(6):718-726. PubMed ID: 28727951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial Activity of Telavancin Tested
    Duncan LR; Sader HS; Huband MD; Flamm RK; Mendes RE
    Microb Drug Resist; 2020 Aug; 26(8):934-943. PubMed ID: 32049591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR; Smith CJ; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
    Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.